title: [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
abstract: Vernakalant is a new antiarrhythmic drug which is used for rapid conversion of atrial fibrillation. The drug is a relatively atrium-selective K' and Na+ channel blocker, prolonging the atrial refractory period. Clinical trials showed conversion rates of about 50% which is comparable to other antiarrhythmic drugs. Further trials will show if vernakalant is less pro-arrythmogenic than its competitors.
authors.affiliation: medizinjournalistin@gmx.net
authors.forename: Iris
authors.initials: I
authors.lastname: Hinneburg
mesh_terms: D000818:Animals; D000840:Anisoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D026902:Potassium Channel Blockers / Q000627:therapeutic use; D011759:Pyrrolidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D026941:Sodium Channel Blockers / Q000627:therapeutic use
chemical_list: D000840:Anisoles; D000889:Anti-Arrhythmia Agents; D026902:Potassium Channel Blockers; D011759:Pyrrolidines; D026941:Sodium Channel Blockers; C524581:vernakalant